Brind.

Silexion Therapeutics Corp. announced a reverse share split to preserve its Nasdaq listing, focusing on RNAi therapies for KRAS-driven cancers.

2 reports, 2 independent Updated May 26
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Silexion Therapeutics Corp. announced a reverse share split to preserve its Nasdaq listing, focusing on RNAi therapies for KRAS-driven cancers.

Who's involved

What this event is mainly about
Nasdaq

How it developed

Newest first. Tap a step to see who reported it.
  1. Silexion Therapeutics Corp. pioneers RNAi therapies for KRAS-driven cancers, establishing partnerships with AMS and Catalent.Sub-event
  2. Silexion Therapeutics Corp. executed a reverse share split to maintain its Nasdaq listing.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GlobeNewswireSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation New Results Reveal Unprec